The Children's Medical Center Corporation Patent applications |
Patent application number | Title | Published |
20160067190 | INJECTABLE NANO-NETWORK GELS FOR DIABETES TREATMENT - A system for “smart” delivery of a therapeutic, prophylactic or diagnostic agent, such as glucose-mediated delivery of insulin through an injectable nano-network consisting of oppositely-charged dextran nanoparticles encapsulating insulin and glucose-specific enzymes forming a gel-like 3D scaffold. As demonstrated by the examples, the system effectively dissociates to release insulin in a hyperglycemic condition, where the catalytic conversion of glucose into gluconic acid and the subsequent degradation of polymeric matrix are facilitated. This formulation design provides a delivery strategy for both self-regulated and long-term diabetes management. | 03-10-2016 |
20140363416 | Methods and Compositions for Promoting Glucose Homeostasis - A method of reducing blood glucose in a subject has been developed. In preferred embodiments, the method involves administering to the subject a specific activator of endogenous mitogen-activated protein kinase kinase 6 (MKK3), mitogen-activated protein kinase kinase 6 (MKK4), mitogen-activated protein kinase kinase 6 (MKK6), p38 mitogen-activated protein kinase (p38MAPK), mitogen-activated kinase-activated protein kinase 2 (MK2), or a combination thereof, in an effective amount to reduce blood glucose in a subject. In other embodiments, the method involves administering to the subject a specific activator to increase X-box binding protein 1 (XBP1) phosphorylation on Thr48 and Ser61 in an effective amount to reduce blood glucose in the subject. Methods of identifying agents for reducing blood glucose in a subject are also provided. | 12-11-2014 |
20140348896 | Hydrophobic Tissue Adhesives - Pre-polymers for use as tissue sealants and adhesives, and methods of making and using thereof are provided. The pre-polymers have flow characteristics such that they can be applied through a syringe or catheter but are sufficiently viscous to remain in place at the site of application and not run off the tissue. The pre-polymers are also sufficiently hydrophobic to resist washout by bodily fluids. The pre-polymers are stable in bodily fluids; that is the pre-polymer does not spontaneously crosslink in bodily fluids absent the presence of an intentionally applied stimulus to initiate crosslinking. Upon crosslinking, the adhesive exhibits significant adhesive strength in the presence of blood and other bodily fluids. The adhesive is sufficiently elastic that it is able to resist movement of the underlying tissue. The adhesive can provide a hemostatic seal. The adhesive is biodegradable and biocompatible, causing minimal inflammatory response. | 11-27-2014 |
20140303234 | METHODS FOR THE MODULATION OF ANGIOGENESIS - The present invention relates to methods and compositions for promoting or inhibiting capillary endothelial (CE) cell migration, promoting or inhibiting the formation of CE networks and promoting or inhibiting angiogenesis. Some embodiments relate to methods and compositions for treating angiogenesis-related disorders characterized by loss or decreased angiogenesis. One aspect relates to the use of at least one pro-angiogenic agent selected from at least one of an p190RhoGAP inhibitor, a TFII-I inhibitor a GATA-2 activator for promoting the formation of CE networks and angiogenesis, and methods for treating angiogenesis-related disorders characterized by loss or decreased angiogenesis. Another aspect of the invention related to use of at least one anti-angiogenic agent selected from at least one of an p190RhoGAP activator, a TFII-I activator a GATA-2 inhibitor for inhibiting the formation of CE networks and inhibiting angiogenesis, and methods for treating angiogenesis-related disorders characterized by uncontrolled or elevated angiogenesis. | 10-09-2014 |
20140288103 | Neosaxitoxin Combination Formulations for Prolonged Local Anesthesia - Since each of the site I sodium channel blockers have a unique activity and cannot be used to extrapolate the same effective dosage for another site I sodium channel blocker, studies were conducted to identify dosages of neosaxitoxin (“NeoSTX”) and bupivacaine, alone or in combination with epinephrine, to provide two to three days of pain relief in humans. Bupivacaine-NeoSTX combinations produce more reliable blockade and longer duration blockade compared to NeoSTX alone. The three-way combination of NeoSTX-bupivacaine-epinephrine produces more prolonged local anesthesia than the two-way combination of NeoSTX-bupivacaine. Addition of epinephrine to this NeoSTX-bupivacaine combination dramatically prolongs the duration of complete blockade to a mechanical stimulus. These results led to development of specific combination dosage formulations. | 09-25-2014 |
20140080913 | Sensory-Specific Local Anesthesia and Prolonged Duration Local Anesthesia - Combinations of charged local anesthetics with chemical permeation enhancers have been developed to give long duration block which is selective for sensory block is greatly prolonged by combining the local anesthetic with a permeation enhancer. The selectivity of sensory over motor block is provided by selecting the concentration of the local anesthetic and the permeation enhancer to provide selective permeability of the sensory and motor neurons to the enhancer. | 03-20-2014 |
20140080841 | Chemical Permeation Enhancers Enhance Nerve Blockade by Toxins - Chemical permeation enhancers (CPEs) improve access of local anesthetics to the nerve, thereby improving their performance. Surfactants, representing three CPE sub-groups: anionic, cationic, and nonionic surfactants, were co-injected with tetrodotoxin (TTX) or bupivacaine at the sciatic nerve of Sprague-Dawley rats. All enhancers produced marked concentration-dependent improvements in the frequency and duration of block with TTX but not bupivacaine. An in vitro toxicity assay showed a wide range of CPE myotoxicity, but in vivo histological assessment showed no signs of muscle or nerve damage at concentrations of CPEs that produced a half-maximal increase in the duration of block of TTX. There was no systematic relationship between the enhancers' charge or hydrophobicity and their enhancement of block duration or potency. Thus, CPEs can provide marked prolongation of nerve blockade from TTX, without apparent local tissue toxicity, and therefore enhance the clinical applicability of TTX for prolonged-duration local anesthesia. | 03-20-2014 |
20120165400 | GENE REPAIR INVOLVING IN VIVO EXCISION OF TARGETING DNA - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. | 06-28-2012 |
20120156300 | MICROBUBBLES AND METHODS FOR OXYGEN DELIVERY - Compositions containing a carrier and microbubbles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope. The compositions may be administered to a patient to quickly deliver large amounts of oxygen to the patient's blood supply or directly to a tissue in need of oxygen. The compositions may be administered via injection or as a continuous infusion. The compositions contain a concentrated microbubble suspension, where the suspension contains at least 40 mL oxygen/dL suspension. The microbubbles are preferably less than 20 microns in diameter, more preferably less than 15 microns in diameter. The microbubbles described herein may be administered to a patient in an effective amount to increase in oxygen concentration in the patient's blood, and/or one or more tissues or organs. | 06-21-2012 |
20120034296 | PROLONGED DURATION LOCAL ANESTHESIA WITH MINIMAL TOXICITY - Compositions containing site 1 sodium channel blockers for use as local anesthetics with rapid nerve block, improved potency and efficacy, and no local toxicity have been developed. Liposomes were employed for increased loading of the site 1 sodium channel blocker, producing prolonged duration of block without systemic toxicity. In one embodiment, the compositions contain a site 1 sodium channel blocker alone. In another embodiment, the compositions contain a site 1 sodium channel blocker in combination with a corticosteroid. As demonstrated by the examples, encapsulating site 1 sodium channel blockers in liposomes results in rapid and prolonged nerve block without systemic toxicity, which is enhanced by the addition of a corticosteroid. Fluid liposomes showed more rapid release of STX than did solid ones, and dexamethasone accelerated STX release. | 02-09-2012 |
20110135632 | METHODS FOR THE MODULATION OF ANGIOGENESIS - The present invention relates to methods and compositions of promoting or inhibiting capillary endothelial (CE) cell migration, promoting or inhibiting the formation of CE networks and promoting or inhibiting angiogenesis, and uses thereof. In particular, the present invention relates to methods and compositions for promoting capillary endothelial (CE) cell migration, promoting the formation of CE networks and promoting angiogenesis, and uses thereof for the purposes of treating angiogenesis-related disorders characterized by loss or decreased angiogenesis, such as ischemic injury and the like. One aspect of the invention related to use of at least one pro-angiogenic agent selected from at least one of an p190RhoGAP inhibitor, a TFII-I inhibitor or a GATA-2 activator for promoting the formation of CE networks and promoting angiogenesis, and uses thereof for the purposes of treating angiogenesis-related disorders characterized by loss or decreased angiogenesis. Another aspect of the invention related to use of at least one anti-angiogenic agent selected from at least one of an p190RhoGAP activator, a TFII-I activator or a GATA-2 inhibitor for inhibiting the formation of CE networks and inhibiting angiogenesis, and uses thereof for the purposes of treating angiogenesis-related disorders characterized by uncontrolled or elevated angiogenesis. | 06-09-2011 |
20100203061 | PREVENTION AND TREATMENT OF RETINAL ISCHEMIA AND EDEMA - The present invention relates to methods of treating retinopathy, retinal ischemia and/or retinal edema comprising administering an integrin or integrin subunit antagonist, leukocyte adhesion-inducing cytokine antagonist or growth factor antagonist, a selectin antagonist or adhesion molecule antagonist. | 08-12-2010 |
20100105773 | USE OF RESOLVINS AND DOCOSATRIENES AND ANALOGUES THEREOF FOR THE TREATMENT OF ANGIOGENESIS AND OCULAR NEOVASCULARIZATION - The present invention relates to methods and compositions for the treatment of, or prevention of angiogenesis in a subject. In particular, the present invention relates to methods to treat a subject with, or at risk of developing angiogenesis by administering a pharmaceutical composition comprising a resolvin or resolvin analogue or precursor, and/or a protectin or protectin analogue. In another embodiment, the present invention relates to the use of resolvins and protectins to treat pathologies associated with angiogenesis. | 04-29-2010 |
20090143765 | Device for Mixing and Delivering Fluids for Tissue Repair - A device for mixing and delivering a mixture of fluids to a target site includes a tube for containing the mixture. A compressible auger for mixing the fluids is movably disposed within the tube, one end of the auger being free at the distal end of the tube. A plunger is also movable within the tube in communication with the other end of the auger. When the plunger is moved axially within the tube the auger also moves axially and the auger is compressed to dispense the fluid. The mixing and delivery device can be used with an apparatus for the arthroscopic delivery of a tissue repair material to a repair site. The apparatus includes a first sheath and a second sheath removably attached to the first sheath for delivering the tissue repair material to the repair site. | 06-04-2009 |
20090137518 | Therapeutic Antiangiogenic Endostatin Compositions - Endostatin compositions capable of inhibiting endothelial cell proliferation, inhibiting angiogenesis and causing tumor regression are described. Specifically, amino acid sequences of endostatin proteins and nucleic acid sequences coding for endostatin proteins are provided. | 05-28-2009 |
20090060896 | Gene repair involving in vivo excision of targeting DNA - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. | 03-05-2009 |
20090004163 | METHOD OF ENHANCING PROLIFERATION AND/OR HEMATOPOIETIC DIFFERENTIATION OF STEM CELLS - The present invention provides a method for enhancing the proliferation and/or hematopoietic differentiation and/or maintenance of mammalian stem cells. The method is useful for generating expanded populations of hematopoietic stem cells (HSCs) and thus mature blood cell lineages. This is desirable where a mammal has suffered a decrease in hematopoietic or mature blood cells as a consequence of disease, radiation or chemotherapy. The method of the present invention comprises increasing the intracellular level of a cdx in stem cells, including hematopoietic stem cells, in culture, either by providing an exogenous cdx protein to the cell, or by introduction into the cell of a genetic construct encoding a cdx. The cdx is selected from the cdx family and includes cdx1, cdx2, or cdx4. The cdx may be a wild type protein appropriate for the species from which the cells are derived, or a mutant form of the protein. | 01-01-2009 |